PriceTargets.com logo

NASDAQ:OTLK - Outlook Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.33
  • Forecasted Upside: 365.69 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.36 As of 01/25/2021 01:00 AM ET
▲ +0.03 (2.26%)
1 month | 3 months | 12 months
Get New Outlook Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OTLK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OTLK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.33
▲ +365.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Outlook Therapeutics in the last 3 months. The average price target is $6.33, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 365.69% upside from the last price of $1.36.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Outlook Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/27/2020HC WainwrightLower Price TargetBuy$7.00 ➝ $5.00High
i
Rating by Douglas Tsao at HC Wainwright
8/18/2020OppenheimerLower Price TargetOutperform$9.00 ➝ $8.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/4/2020LADENBURG THALM/SH SHReiterated RatingBuy$6.00Medium
i
6/3/2020OppenheimerInitiated CoverageBuy$9.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
5/27/2020HC WainwrightLower Price TargetBuy$8.00 ➝ $7.00High
i
Rating by Douglas Tsao at HC Wainwright
5/18/2020HC WainwrightReiterated RatingBuy$8.00Medium
i
Rating by Douglas Tsao at HC Wainwright
5/18/2020OppenheimerReiterated RatingBuyHigh
i
5/5/2020Brookline Capital ManagementInitiated CoverageBuyHigh
i
Rating by K. Raja at Brookline Capital Management
4/14/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Douglas Tsao at HC Wainwright
9/11/2019LADENBURG THALM/SH SHInitiated CoverageBuy$9.00High
i
7/18/2019HC WainwrightInitiated CoverageBuy$8.00High
i
Rating by D. Tsao at HC Wainwright
5/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$12.00High
i
5/16/2019OppenheimerInitiated CoverageOutperform$12.00 ➝ $12.00High
i
4/22/2019Ascendiant Capital MarketsInitiated CoverageBuy ➝ Buy$4.00High
i
(Data available from 1/25/2016 forward)
Outlook Therapeutics logo
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.
Read More

Today's Range

Now: $1.36
$1.32
$1.40

50 Day Range

MA: $1.33
$1.15
$1.58

52 Week Range

Now: $1.36
$0.50
$1.73

Volume

628,937 shs

Average Volume

767,732 shs

Market Capitalization

$172.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Outlook Therapeutics?

The following equities research analysts have issued stock ratings on Outlook Therapeutics in the last twelve months: Brookline Capital Management, HC Wainwright, LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., and Zacks Investment Research.

What is the current price target for Outlook Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Outlook Therapeutics in the last year. Their average twelve-month price target is $6.33, suggesting a possible upside of 365.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting OTLK will reach $8.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Outlook Therapeutics in the next year.

What is the current consensus analyst rating for Outlook Therapeutics?

Outlook Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OTLK will outperform the market and that investors should add to their positions of Outlook Therapeutics.

What other companies compete with Outlook Therapeutics?

Other companies that are similar to Outlook Therapeutics include Osiris Therapeutics, DBV Technologies, Curis, Orchard Therapeutics, SQZ Biotechnologies, CEL-SCI, MeiraGTx, Poseida Therapeutics, AVROBIO, Codiak BioSciences, Harpoon Therapeutics, Oyster Point Pharma, Fusion Pharmaceuticals, Jounce Therapeutics and Surface Oncology.

How do I contact Outlook Therapeutics' investor relations team?

Outlook Therapeutics' physical mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The company's listed phone number is 609-619-3990 and its investor relations email address is [email protected] The official website for Outlook Therapeutics is www.outlooktherapeutics.com.